Ventas (FRA:VEN) Other Stockholders Equity: €-0 Mil (As of Mar. 2026)


FRA:VEN Ventas Inc FRA:VEN
80 GF Score
Price €80.56
GF Value €61.17
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Ventas Other Stockholders Equity?

Ventas FRA:VEN +0.65% 80 Other Stockholders Equity is €-0 Mil as of Mar. 2026. GuruFocus rates FRA:VEN with a GF Score™ of 80/100 and a GF Value™ of €61.17 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Ventas's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €-0 Mil.

Ventas's quarterly Other Stockholders Equity declined from Sep. 2025 (€0 Mil) to Dec. 2025 (€-0 Mil) but then stayed the same from Dec. 2025 (€-0 Mil) to Mar. 2026 (€-0 Mil).

Ventas's annual Other Stockholders Equity declined from Dec. 2023 (€0 Mil) to Dec. 2024 (€0 Mil) and declined from Dec. 2024 (€0 Mil) to Dec. 2025 (€-0 Mil).

Ventas Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Ventas's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ventas Other Stockholders Equity Chart

Ventas Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00

Ventas Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 -0.00
FRA:VEN
80GF Score
Ventas Inc FRA:VEN
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ventas Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-0 Mil mean?
Ventas (FRA:VEN) has a Other Stockholders Equity of €-0 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Ventas and its competitors.
Is Ventas' Other Stockholders Equity too high?
Ventas' current Other Stockholders Equity is €-0 Mil. Overall, Ventas has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ventas' Other Stockholders Equity compare to DOC and OHI?
Ventas' Other Stockholders Equity of €-0 Mil can be compared against companies in the REITs industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a REITs company?
A good Other Stockholders Equity depends on the REITs industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Ventas and its competitors. Ventas's current Other Stockholders Equity is €-0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ventas stock overvalued right now?
Based on GuruFocus' analysis, Ventas (FRA:VEN) is currently considered Significantly Overvalued. The stock's GF Value™ is €61.17, compared to a current price of €80.56 — trading 31.7% above its estimated fair value. The current Other Stockholders Equity is €-0 Mil. Ventas' overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Ventas (FRA:VEN), the current Other Stockholders Equity is €-0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ventas (FRA:VEN) Overvalued in 2026?

Based on GuruFocus' analysis, Ventas stock appears to be overvalued. The current stock price of €80.56 is trading 31.7% above its estimated GF Value™ of €61.17. GuruFocus considers Ventas to be Significantly Overvalued.

Key valuation signals for FRA:VEN:

  • Other Stockholders Equity: €-0 Mil
  • GF Value™: €61.17 vs. price of €80.56 (31.7% above fair value)
  • GF Score™: 80/100 with 8 warning signs

No single metric tells the full story. See the FRA:VEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ventas Business Description

Industry Real EstateREITs
Address 300 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60654
Ventas owns a diversified healthcare portfolio of almost 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes almost 100 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 1% of net operating income.
80GF Score

Get the complete analysis for FRA:VEN

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€80.56
Price
€61.17
GF Value